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Summary
Chronic graft-versus-host disease (cGVHD) is a multi-organ alloimmune and autoimmune 
disease occurring after allogeneic hematopoietic stem cell transplantation (alloHSCT). Due to 
increasing safety of alloHSCT number of survivors is increasing and more patients are at risk of 
developing cGVHD. Low platelet counts in cGVHD patients are predictors of poor survival acro-
ss many cGVHD studies; however, such association is still not well understood. Moreover, newer 
studies found increased platelet counts and active thrombopoiesis associated with more active 
and more severe cGVHD. Several acquired disorders of coagulation are described in cGVHD 
patients as well. Hemostatic disorders in the setting of cGVHD have multifactorial etiology with 
numerous interactions between inflammation and coagulation. Improved understanding of these 
processes may lead to better understanding of pathophysiology of cGVHD and to improve pre-
vention and treatment of that severe disease. 
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INTRODUCTION 
Allogeneic hematopoietic stem cell transplantation (alloHSCT) is an intensive 
curative therapy used to treat numerous high-risk hematological malignant and 
non-malignant diseases [1]. Over the past decade, the improvement were made 
in supportive care, graft-versus-host disease (GVHD) prophylaxis, better mana-
gement of early complications, new stem cell sources, DNA-based tissue typing, 
new conditioning regimens with less toxicity, resulting in improved outcomes. 
The number of alloHSCT continues to increase with more than 25 000 performed 
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annually [1]. Recent study showed substantial reduction in early death related to 
alloHSCT and improved long-term survival after alloHSCT due to reduction in or-
gan damage, infection and severe acute GVHD [2]. However, long-term survivors 
experience several long-term complications such as chronic GVHD, metabolic and 
endocrinology abnormalities, decreased quality of life and secondary malignan-
ces, and mortality rates remain twice as high as that of the general population 
among 15-year survivors of alloHSCT [3]. 
Chronic graft versus host disease (cGVHD) is a major late complication occu-
rring in 25-80% of alloHSCT recipients [4]. It is a multi-organ alloimmune and autoi-
mmune disease characterized by immune deregulation, immunodeficiency, develo-
pment of signs and symptoms of different autoimmune or immunologic disorders, 
and is associated with decreased survival [4-7].
Platelets and chronic gVHD
Thrombocytopenia in cGVHD patients is among the most consistent and stron-
gest negative survival predictors across many cGVHD studies, as it is extensively 
reviewed by Pulanic and colleagues [8]. One among the earliest studies which 
showed that cGVHD patients with low platelet counts had the worst survival and 
that thrombocytopenia may reflect more severe cGVHD was study by First and 
colleagues published in 1985 [9]. A few years later Sullivan with colleagues stu-
died 179 patients with extensive cGVHD, and those with thrombocytopenia less 
than 100,000/μL had increased mortality [10]. Another important study was publis-
hed in 1989 by Anasetti and colleagues [11]. This study concluded that persistent 
thrombocytopenia after alloHSCT is most often secondary to increased platelet 
destruction mediated by multiple mechanisms, and that increased mortality of 
patients with cGVHD and thrombocytopenia may be result of underlying immu-
nodeficiency and immune deregulation [11]. Akpek with colleagues defined 3 risk 
factors at diagnosis of cGVHD that were significantly associated with increased 
non-relapse mortality: thrombocytopenia (platelets less than 100,000/μL), more 
than 50% body surface area skin involvement and progressive type of cGVHD on-
set [12]. Study of Przepiorka and colleagues validated risk stratification by platelet 
count in 116 alloHSCT patients [13]. Long term progression-free survival was 31% 
for patients without cGVHD, 51% for not thrombocytopenic cGVHD patients and 
just 16% for patients with cGVHD and thrombocytopenia [13]. Large multicenter 
study published by Akpek and colleagues in 2003 with a total of 1105 cGVHD 
patients from 4 different cohorts showed that thrombocytopenia (platelets less 
than 100,000/μL) was uniformly associated with increased risk of mortality acro-
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ss all cohorts [14]. Arora and colleagues studied 159 cGVHD patients to identify 
predictors of response and long-term mortality [15]. In multivariate analysis age 
older than 20 years, progressive onset of cGVHD, gastrointestinal tract involve-
ment and platelets less than 100,000/μL were associated with increased mortality 
[15]. Pavletic and colleagues identifies several independent prognostic risk factors 
for cGVHD incidence and severity comparing bone marrow (75 patients, alloBMT 
group) and peripheral blood alloHSCT (87 patients, alloPSCT group) recipients, 
suggesting that stem cell source may influence not just the incidence of cGVHD 
but also its characteristics [5]. Predictive factors for poor survival at 3 years after 
cGVHD diagnosis in alloPSCT patients were platelets below 100,000/μL and hi-
story of acute GVHD of the liver, and only low platelet count remained predictive 
for poor survival in alloBMT group [5]. Arora with colleagues in 2007 analyzed 
clinical presentation and response to treatment in 170 patients with cGVHD (123 
after transplant from an unrelated donor and 47 from umbilical cord blood) (16). In 
both cohorts thrombocytopenia and not achieving complete or partial remission 
at 2 months were independently associated with increased mortality [16].
Several possible mechanisms of thrombocytopenia in the cGVHD setting were 
suggested: transplant-related thrombocytopenia, malignancy relapse, microangi-
opatic thrombocytopenia, drug-induced thrombocytopenia, immune-mediated 
thrombocytopenia, hypersplenism, infection, cytokine-induced thrombocytope-
nia (increased transforming growth factor-beta (TGF-β), low thrombopoietin le-
vel, other cytokines) [8]. 
In contrast, in the recent study by Grkovic and colleagues higher platelet co-
unts were associated with more active and more severe chronic cGVHD [17]. In 
that study markers of inflammation were studied among 189 adult patients with 
chronic cGVHD and were correlated with disease activity and severity [17]. 
Higher platelets were associated with most severe skin (p=0.0016) and joint/fascia 
cGVHD involvement (p=0.0001) [17]. This relationship was hypothesized to be re-
lated to ongoing inflammation and reactive thrombocytosis mediated by IL-6, a 
strong stimulator of platelet production [17]. Moreover, platelets can contribute to 
pathogenesis of fibrosis as they are important source of fibrogenic cytokines such 
as TGF-β and platelet-derived growth factor (PDGF) [17]. In addition to that, Bat 
with colleagues recently found that active thrombopoiesis, measured by the abso-
lute immature platelet number in the blood, was associated with worse severity 
and activity of chronic cGVHD, especially skin and joints/fascia manifestations, 
supporting hypothesis that ongoing inflammation in cGVHD stimulates increa-
sed thrombopoiesis in the most severe patients [18].
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Acquired coagulation disorders and chronic gVHD 
Patients with cGVHD may develop several other acquired coagulation disor-
ders, including also an increased risk for venous thrombosis in spite of higher blee-
ding risk [8]. 
Pihusch et al [19] retrospectively analyzed hemostatic complications among 447 
hematopoietic stem cell transplantation (HSCT) patients. The 364 alloHSCT patients 
had a higher incidence and severity of hemorrhagic complications than autologous 
HSCT patients, what was due to GVHD: patients with acute GVHD greater than gra-
de I had a three-fold higher risk of bleeding, chronic GVHD patients had a four-fold 
higher risk, with an eleven-fold risk of severe hemorrhage. Such GVHD-associated 
bleeding was mostly localized in GVHD affected organs like skin and gastrointesti-
nal tract and it correlated with an increased mortality. The authors concluded that 
acute and chronic GVHD strongly increase bleeding risk by destruction of epithe-
lium and hyperperfusion and proliferation of the blood vessels [19]. In the same 
study, venous thromboembolism (VTE) occurred mostly later after transplantation 
and depended on the type of transplantation. Chronic GVHD and treatment with 
steroids were the most important risk factors for VTE [19]. The authors suggested 
that cytokines which modulate endothelial hemostatic function could be responsi-
ble for VTE in cGVHD. Other work from the same group of authors prospectively 
studied the impact of GVHD and of thrombophilic gene mutations in 89 alloHSCT 
patients [20]. They again reported increased risk for VTE among cGVHD patients 
[20]. In that work, thrombophilic gene mutations and polymorphisms did not influ-
ence either the incidence of any of the major transplant-related complications or the 
bleeding incidence [20]. Among patients with thromboembolic complications those 
with catheter thromboses and hepatic veno-occlusive disease showed an increased 
frequency of the 4G allele of the PAI-1 gene, while other tested thrombophilic gene 
mutations and polymorphisms had no impact on the incidence of VTE complicati-
ons among alloHSCT patients [20]. 
Other acquired hemostatic disorders in chronic GVHD patients are rare and 
are described in several case reports [8]: acquired hemophilia A (acquired factor 
VIII inhibitor) [21], acquired von Willebrand’s disease [22], antiphospholipid syn-
drome (APS) [23], catastrophic APS [24], passive donor-to-recipient transfer of APS 
following the onset of cGVHD [25]. 
It is important to note the link between von Willebrand's factor (vWF), endothe-
lial injury and chronic GVHD described by Biedermann and colleagues [26]. They 
found that chronic GVHD patients have extensive loss of microvessels in affected 
tissues and increased circulating vWF concentrations, concluding that vWF was 
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released from vascular endothelial cells injured in process of cGVHD [26]. Since 
elevated vWF and factor VIII (FVIII) levels have been described as indicators of en-
dothelial dysfunction and inflammation in different settings, our Zagreb’s cGVHD 
group assessed possible role of vWF and FVIII as potential biomarkers of cGVHD 
[27]. Preliminary results of this pilot study presented recently at the European Bone 
Marrow Transplantation meeting suggest that vWF and FVIII could represent in-
teresting candidate biomarkers of cGVHD, what need to be further investigated in 
larger studies [27]. 
CONCLUSION
Platelet and coagulation disorders in the setting of chronic GVHD have multifac-
torial etiology with numerous interactions between inflammation and hemostasis. Im-
proved understanding of these processes may lead to better understanding of pathop-
hysiology of cGVHD and to improve prevention and treatment of that severe disease. 
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Sažetak
Trombociti i koagulacija u kroničnoj bolesti presatka protiv primatelja
Kronična bolest presatka protiv primatelja (eng. chronic graft-versus-host disease, cGVHD) 
je multiorganska aloimuna i autoimuna bolest koja nastaje nakon transplantacije alogeničnih 
krvotvornih matičnih stanica (aloTKMS). S obzirom na poboljšanje sigurnosti transplantacije i na 
porast preživljenja nakon aloTKMS, sve više osoba nakon aloTKMS ima rizik nastanka cGVHD. 
Trombocitopenija u cGVHD bolesnika je prediktor lošeg preživljenja u brojnim studijama 
cGVHD, iako ta povezanost još uvijek nije dobro objašnjena. Nove studije su utvrdile poveza-
nost povišenih trombocita i aktivne trombocitopoeze s aktivnijim i težim cGVHD. Više stečenih 
poremećaja koagulacije opisano je u cGVHD bolesnika. Hemostatski poremećaji u cGVHD 
imaju multifaktorijalnu etiologiju s brojnim interakcijama između upale i koagulacije. Unaprije-
đenje razumijevanja tih procesa dovest će do boljeg razumijevanja patofiziologije cGVHD, kao 
i prevencije i liječenja te teške bolesti. 
Ključne riječi: trombociti, trombocitopenija, trombocitopoeza, poremećaji koagulacije, kro-
nična bolest presatka protiv primatelja
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